 | • レポートコード：QYR2104Z1316 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、慢性炎症性脱髄性多発神経炎（CIDP）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（コルチコステロイド療法、IVIG治療、血漿交換療法、免疫抑制薬療法、免疫調節剤療法、その他）、用途別市場規模（病院、専門神経内科クリニック、研究・学術研究所）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・慢性炎症性脱髄性多発神経炎（CIDP）の市場動向 ・企業の競争状況、市場シェア ・慢性炎症性脱髄性多発神経炎（CIDP）の種類別市場規模（コルチコステロイド療法、IVIG治療、血漿交換療法、免疫抑制薬療法、免疫調節剤療法、その他） ・慢性炎症性脱髄性多発神経炎（CIDP）の用途別市場規模（病院、専門神経内科クリニック、研究・学術研究所） ・慢性炎症性脱髄性多発神経炎（CIDP）の北米市場規模2016-2027（アメリカ、カナダ） ・慢性炎症性脱髄性多発神経炎（CIDP）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・慢性炎症性脱髄性多発神経炎（CIDP）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・慢性炎症性脱髄性多発神経炎（CIDP）の中南米市場規模2016-2027（メキシコ、ブラジル） ・慢性炎症性脱髄性多発神経炎（CIDP）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Teijin Pharma、Shire、Pfizer、Octapharma、Momenta Pharmaceuticals、Mitsubishi Tanabe Pharma Corporation、Kedrion、Grifols、CSL Behring (CSL Limited)、Bio Products Laboratory、Baxter、MedDay Pharmaceuticals、GeNeuro Pharmaceuticals） ・結論 |
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune motor sensory peripheral neuropathy with chronic demyelination of the proximal peripheral nerves as the main lesion. It belongs to chronic acquired demyelinating multiple neuropathy (ADP), the most common type of CADP, and presents a course of chronic progression or remission – recurrence.
Market Analysis and Insights: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Scope and Market Size
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Corticosteroid Therapy
IVIG Treatment
Plasma Exchange Therapy
Immunosuppressive Drug Therapy
Immunomodulator Therapy
Other
Segment by Application
Hospital
Specialist Neurology Clinic
Research and Academic Laboratories
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Teijin Pharma
Shire
Pfizer
Octapharma
Momenta Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Kedrion
Grifols
CSL Behring (CSL Limited)
Octapharma
Momenta Pharmaceuticals
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Corticosteroid Therapy
1.2.3 IVIG Treatment
1.2.4 Plasma Exchange Therapy
1.2.5 Immunosuppressive Drug Therapy
1.2.6 Immunomodulator Therapy
1.2.7 Other
1.3 Market by Application
1.3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Specialist Neurology Clinic
1.3.4 Research and Academic Laboratories
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Perspective (2016-2027)
2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Trends by Regions
2.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Share by Regions (2016-2021)
2.2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Regions (2022-2027)
2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Dynamic
2.3.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends
2.3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers
2.3.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Challenges
2.3.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue
3.1.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue (2016-2021)
3.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Players (2016-2021)
3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue
3.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio
3.4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2020
3.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players Head office and Area Served
3.6 Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service
3.7 Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Type
4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Type (2016-2021)
4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2022-2027)
5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Application
5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Application (2016-2021)
5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
6.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
6.2.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
6.2.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
6.2.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
6.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
6.3.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
6.3.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
6.3.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
6.4 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country
6.4.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021)
6.4.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
7.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
7.2.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
7.2.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
7.2.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
7.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
7.3.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
7.3.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
7.3.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
7.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country
7.4.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021)
7.4.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
8.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
8.2.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
8.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
8.3.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
8.4 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region
8.4.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
9.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
9.2.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
9.2.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
9.2.3 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
9.3 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
9.3.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
9.3.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
9.3.3 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
9.4 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country
9.4.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021)
9.4.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
10.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
10.2.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
10.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
10.3.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
10.4 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country
10.4.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Teijin Pharma
11.1.1 Teijin Pharma Company Details
11.1.2 Teijin Pharma Business Overview
11.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.1.4 Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.1.5 Teijin Pharma Recent Development
11.2 Shire
11.2.1 Shire Company Details
11.2.2 Shire Business Overview
11.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.2.4 Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.2.5 Shire Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.3.4 Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Octapharma
11.4.1 Octapharma Company Details
11.4.2 Octapharma Business Overview
11.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.4.4 Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.4.5 Octapharma Recent Development
11.5 Momenta Pharmaceuticals
11.5.1 Momenta Pharmaceuticals Company Details
11.5.2 Momenta Pharmaceuticals Business Overview
11.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.5.4 Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.5.5 Momenta Pharmaceuticals Recent Development
11.6 Mitsubishi Tanabe Pharma Corporation
11.6.1 Mitsubishi Tanabe Pharma Corporation Company Details
11.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview
11.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.6.4 Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.6.5 Mitsubishi Tanabe Pharma Corporation Recent Development
11.7 Kedrion
11.7.1 Kedrion Company Details
11.7.2 Kedrion Business Overview
11.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.7.4 Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.7.5 Kedrion Recent Development
11.8 Grifols
11.8.1 Grifols Company Details
11.8.2 Grifols Business Overview
11.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.8.4 Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.8.5 Grifols Recent Development
11.9 CSL Behring (CSL Limited)
11.9.1 CSL Behring (CSL Limited) Company Details
11.9.2 CSL Behring (CSL Limited) Business Overview
11.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.9.4 CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.9.5 CSL Behring (CSL Limited) Recent Development
11.10 Bio Products Laboratory
11.10.1 Bio Products Laboratory Company Details
11.10.2 Bio Products Laboratory Business Overview
11.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.10.4 Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.10.5 Bio Products Laboratory Recent Development
11.11 Baxter
11.11.1 Baxter Company Details
11.11.2 Baxter Business Overview
11.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.11.4 Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.11.5 Baxter Recent Development
11.12 MedDay Pharmaceuticals
11.12.1 MedDay Pharmaceuticals Company Details
11.12.2 MedDay Pharmaceuticals Business Overview
11.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.12.4 MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.12.5 MedDay Pharmaceuticals Recent Development
11.13 GeNeuro Pharmaceuticals
11.13.1 GeNeuro Pharmaceuticals Company Details
11.13.2 GeNeuro Pharmaceuticals Business Overview
11.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
11.13.4 GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
11.13.5 GeNeuro Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Corticosteroid Therapy
Table 3. Key Players of IVIG Treatment
Table 4. Key Players of Plasma Exchange Therapy
Table 5. Key Players of Immunosuppressive Drug Therapy
Table 6. Key Players of Immunomodulator Therapy
Table 7. Key Players of Other
Table 8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2016-2021)
Table 12. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2022-2027)
Table 14. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends
Table 15. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers
Table 16. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Challenges
Table 17. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints
Table 18. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players (2016-2021)
Table 20. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2020)
Table 21. Ranking of Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service
Table 25. Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2016-2021)
Table 29. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2016-2021)
Table 33. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027) & (US$ Million)
Table 65. Teijin Pharma Company Details
Table 66. Teijin Pharma Business Overview
Table 67. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 68. Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 69. Teijin Pharma Recent Development
Table 70. Shire Company Details
Table 71. Shire Business Overview
Table 72. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 73. Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 74. Shire Recent Development
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 78. Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 79. Pfizer Recent Development
Table 80. Octapharma Company Details
Table 81. Octapharma Business Overview
Table 82. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 83. Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 84. Octapharma Recent Development
Table 85. Momenta Pharmaceuticals Company Details
Table 86. Momenta Pharmaceuticals Business Overview
Table 87. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 88. Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 89. Momenta Pharmaceuticals Recent Development
Table 90. Mitsubishi Tanabe Pharma Corporation Company Details
Table 91. Mitsubishi Tanabe Pharma Corporation Business Overview
Table 92. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 93. Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 94. Mitsubishi Tanabe Pharma Corporation Recent Development
Table 95. Kedrion Company Details
Table 96. Kedrion Business Overview
Table 97. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 98. Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 99. Kedrion Recent Development
Table 100. Grifols Company Details
Table 101. Grifols Business Overview
Table 102. Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 103. Grifols Recent Development
Table 104. CSL Behring (CSL Limited) Company Details
Table 105. CSL Behring (CSL Limited) Business Overview
Table 106. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 107. CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 108. CSL Behring (CSL Limited) Recent Development
Table 109. Bio Products Laboratory Company Details
Table 110. Bio Products Laboratory Business Overview
Table 111. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 112. Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 113. Bio Products Laboratory Recent Development
Table 114. Baxter Company Details
Table 115. Baxter Business Overview
Table 116. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 117. Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 118. Baxter Recent Development
Table 119. MedDay Pharmaceuticals Company Details
Table 120. MedDay Pharmaceuticals Business Overview
Table 121. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 122. MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 123. MedDay Pharmaceuticals Recent Development
Table 124. GeNeuro Pharmaceuticals Company Details
Table 125. GeNeuro Pharmaceuticals Business Overview
Table 126. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
Table 127. GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
Table 128. GeNeuro Pharmaceuticals Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type: 2020 VS 2027
Figure 2. Corticosteroid Therapy Features
Figure 3. IVIG Treatment Features
Figure 4. Plasma Exchange Therapy Features
Figure 5. Immunosuppressive Drug Therapy Features
Figure 6. Immunomodulator Therapy Features
Figure 7. Other Features
Figure 8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2020 VS 2027
Figure 9. Hospital Case Studies
Figure 10. Specialist Neurology Clinic Case Studies
Figure 11. Research and Academic Laboratories Case Studies
Figure 12. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Years Considered
Figure 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions: 2020 VS 2027
Figure 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2022-2027)
Figure 17. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players in 2020
Figure 18. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2020
Figure 20. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2016-2021)
Figure 21. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2022-2027)
Figure 22. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
Figure 24. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
Figure 25. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2016-2027)
Figure 26. United States Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
Figure 30. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
Figure 31. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2016-2027)
Figure 32. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region (2016-2027)
Figure 42. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
Figure 50. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
Figure 51. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2016-2027)
Figure 52. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2016-2027)
Figure 58. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Teijin Pharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 62. Shire Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 64. Octapharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 65. Momenta Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 66. Mitsubishi Tanabe Pharma Corporation Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 67. Kedrion Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 68. Grifols Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 69. CSL Behring (CSL Limited) Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 70. Bio Products Laboratory Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 71. Baxter Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 72. MedDay Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 73. GeNeuro Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
世界の抗炎症療法市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Anti-inflammatory Therapy Market The global Anti-inflammatory Therapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, th…- 世界の家族性アミロイド多発神経障害市場規模・現状・予測（2021年-2027年） Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle. Globally, development of new dru…
- 世界の家族性アミロイド多発神経障害市場規模・現状・予測（2021年-2027年） Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle. Globally, development of new dru…
- 世界の免疫細胞療法市場規模・現状・予測（2021年-2027年） Immune therapy is a new class of cancer treatment designed to boost or enhance the body’s immune system to more efficiently target and destroy cancerous cells. Many experts believe that immunotherapy represents the most promising new cancer treatment since the development of chemotherapy. Market Ana…
- 世界の心臓再同期療法（CRT）市場規模・現状・予測（2021年-2027年） Cardiac resynchronisation therapy (CRT) is the insertion of electrodes in the left and right ventricles of the heart, as well as on occasion the right atrium, to treat heart failure by coordinating the function of the left and right ventricle. CRT-D is expected to dominate the CRT market owing to th…